7月28日 - ** 药物开发商CervoMed CRVO.O股价盘前上涨58.7%至14.25美元
** 该公司称 (link)，根据其中期试验的32周扩展数据，其试验性药物neflamapimod明显减缓了路易体痴呆患者的疾病进展，路易体痴呆是痴呆症的第二大常见形式。
** 去年 12 月，该药物在同一试验中未能达到主要和次要目标 (link)，导致其股价下跌了 79%。
** 该公司称，与未服用该药的患者相比，服用奈夫拉马莫德的患者病情恶化的风险降低了54%。
** Neflamapimod还能减少表明脑细胞受损的血液标记物
** CRVO计划在2025年第四季度与FDA会面，讨论后期试验事宜
** 截至上次收盘，股价
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.